pain associated News
-
Panag Pharma Inc. Announces Initiation Of A Clinical Trial
Halifax, Nova Scotia. Panag Pharma, Inc. launched a clinical trial evaluating the use of the newly NHP registered product Topical AOTC, a new generation topical for pain and pain associated with inflammation. Topical AOTC is a Health Canada approved natural health product indicated for temporary relief of aches and pains of muscles and joints associated with simple backache, lumbago, ...
-
Panag Pharma announces health Canada License for a topical cold-sore formulation NPN 80084806
Halifax, Nova Scotia. Panag Pharma announces Health Canada approval for a topical Cold-Sore Formulation, a new generation topical formulation with a dual mechanism of action that improves healing rates and reduces symptoms, i.e. pain, associated with herpes labialis (cold sores). The topical Cold-Sore Formulation is a natural health product indicated for the relief of symptoms associated ...
-
A new study confirming correlation between Biomechanical Markers and clinical outcomes in knee OA patients
A new study published in BMC Musculoskeletal Disorders confirmed that biomechanical markers are more associated with pain, symptoms and disability compared to imaging findings in knee osteoarthritis patients. Researchers recommend the use of a complementary objective biomechanical evaluation using the KneeKG to conventional imaging to obtain a more complete functional profile of knee OA ...
By Emovi
-
Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702
THOUSAND OAKS, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that it will host a key opinion leader (KOL) webinar on gout on Tuesday, November 23, 2021 at 11:00am Eastern Time. A live Q&A session will follow the formal presentations. To register for the event, please click HERE. The webinar will ...
-
electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States for patients suffering from pain associated with different forms of ...
-
FDA Approves Theranica`s Nerivio® for Acute Treatment of Migraine in Adolescents
Theranica, a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio® therapeutic device has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older. The use of the device in the ...
-
gammaCore Sapphire Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium. CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout ...
-
ZetaMet™ Receives Health Canada Authorization for Phase 2a Study in Treating Metastatic Bone Lesions
Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Study will examine the safety and efficacy of ZetaMetTM in the treatment of metastatic bone lesions as part of advanced stage cancer therapy Study is targeting Stage 4 breast cancer patients who have metastatic lesions in their spinal vertebrae Zetagen Therapeutics, a private, ...
-
electroCore, Inc. Announces Study of gammaCore Sapphire for the Treatment of Post-COVID Syndrome
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) in patients with post-COVID syndrome. Post-COVID syndrome, also known as Long COVID, is a collection of symptoms that persist greater than 28 days ...
-
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration, a major cause of ...
-
electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within selected managed care health systems. ...
-
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease
Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results in the second half of this year XyloCor ...
-
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical Care Society’s (NCS) 20th Annual Meeting held in San Antonio, Texas on October 17 – 21, 2022 on the possible role of gammaCore (nVNS) in the acute treatment of Traumatic Brain Injury (TBI). The presentation is being given by Dr. Afshin ...
-
Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center
CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced a joint, two-year research collaboration with Moffitt Cancer Center. The collaboration will study Dyve’s systemic buffering agent, ...
-
Dental volunteers for Israel honors Henry Schein`s Steve Kess at 30th anniversary Gala
Dental Volunteers for Israel (DVI), which is celebrating 30 years of providing oral health care services to underserved families in Jerusalem, regardless of background, honored four people who have helped support the organization, at their New York gala held this week at the Museum of Jewish Heritage in New York City. The honorees were Steve Kess, Vice President of Global Professional Relations ...
-
Saluda Medical Receives FDA Approval for the Evoke® Spinal Cord Stimulation System to Treat Chronic Intractable Pain
Transformative closed-loop technology senses the spinal cord’s response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment Long-term results published in two premier clinical journals show clinically meaningful improvements in pain relief, physical and emotional functioning, sleep quality, and health-related quality of life Saluda Medical Pty ...
-
Berkshire Biomedical Recognizes International Overdose Awareness Day
Berkshire Biomedical, LLC (“Berkshire” or “the Company”), focused on developing drug delivery devices designed to precisely deliver oral liquid drugs only to the biometrically authenticated Intended User, provide remote monitoring and enhance patient wellness, announces today that it joins with the millions of advocates around the world in recognition of International ...
-
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder: A Double-Blind, Randomized, Sham-Controlled Pilot Study in the journal, Brain Stimulation. The ...
-
Why Innovation in Blood Testing Matters
Why should payers care about clinical laboratory testing? Clinical laboratory testing plays an essential role in the delivery of health care. From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. Seventy percent of medical decisions depend on lab test results, so making ...
-
XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT
Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study – Preliminary efficacy data highlight XC001 potential for patients with refractory angina with no other treatment options – Treatment strategy is to use local ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you